Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Christina Jones filed a Form 144 reporting the sale of 2,811 shares of Common Stock under a 10b5-1 plan. The filing lists the securities as Restricted Stock Units with an effective broker entry dated 06/04/2026.
The filing also records prior sales of 1,998 shares on 05/21/2026 with an aggregate amount of $19,880.10 reported for those transactions.
BBNX filed a Rule 144 notice listing an equity award of 275 shares to be sold for cash, dated 06/01/2026 with a filing date of 06/04/2026.
The filing also discloses recent sales by Mark Hopman of 5,329 shares on 06/02/2026 for $68,157.91 and 353 shares on 03/04/2026 for $4,084.21. Shares outstanding are listed as 44,024,631 as of 06/04/2026.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a small share sale primarily for tax purposes. He sold 4,378 shares of Common Stock on June 2, 2026 at a weighted average price of $12.6071 per share, within a price range of $12.30 to $12.93.
According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units rather than a discretionary portfolio decision. After this transaction, Mensinger still directly owns 184,415 shares of Beta Bionics common stock.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of 5,329 shares of Common Stock. The shares were sold at a weighted average price of $12.6071 per share to cover tax withholding obligations tied to the vesting of restricted stock units, according to the footnotes. After this transaction, Hopman directly holds 130,887 shares of Beta Bionics common stock, indicating that the sale represents a relatively small portion of his overall position and is primarily a tax-related event rather than a discretionary reduction in ownership.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported an open-market sale of 4,222 shares of common stock on June 2, 2026. The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
The weighted average sale price was $12.6071 per share, with individual trade prices ranging from $12.30 to $12.93. After these transactions, he directly holds 173,849 shares of Beta Bionics common stock, indicating this was a relatively small, tax-driven sale.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an open-market sale of 6,676 shares of common stock. The shares were sold on June 2, 2026 primarily to cover tax withholding obligations tied to vesting restricted stock units. The weighted average sale price was $12.6071 per share, with trade prices ranging from $12.30 to $12.93. Following this tax-related sale, Feider directly holds 166,053 shares of Beta Bionics common stock.
Beta Bionics, Inc. President & CEO Sean Saint reported an open-market sale of 16,872 shares of common stock at a weighted average price of $12.6071 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and he now holds 420,937 shares directly.
BBNX submitted a Form 144 notice reporting the planned sale of Common Stock tied to Restricted Stock Units vesting under a registered plan, with an event date of 06/01/2026 and a filing date of 06/02/2026. The filing lists “Compensation for services rendered to Issuer” as the source.
BBNX submitted a Form 144 notice regarding proposed sales of Common Stock linked to Restricted Stock Units vesting under a registered plan. The filing lists 4,222 shares and identifies Morgan Stanley Smith Barney LLC as broker. The securities are described as compensation for services rendered to the issuer with dates anchored 06/01/2026 and 06/02/2026.
Beta Bionics reported a Form 144 notice by Michael Mensinger proposing the sale of 4,378 shares of Common Stock. The filing shows the securities relate to Restricted Stock Units vesting under a registered plan with a vesting date of 06/01/2026. The cover line lists a value of $55,994.62 and a reference share count of 44,561,695.